Escitalopram Oxalate

ApprovedSmall molecule

TTorrent Pharmaceuticals Limited

Escitalopram Oxalate is one of 141 small molecule programs targeting Intestinal Cancer. It is currently in Approved.

Indications

Total Trials

Active Trials

140

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intestinal CancerActive, not recruiting

Panic DisorderActive, not recruiting

Breast CancerActive, not recruiting

Spinal Cord InjuryActive, not recruiting

Intestinal CancerPhase 3

Active, not recruiting

Panic DisorderApproved

Active, not recruiting

Breast CancerPreclinical

Active, not recruiting

Spinal Cord InjuryPreclinical

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Escitalopram Oxalate

TTorrent Pharmaceuticals Limited

Approved

1 2

Tecentriq

Roche

Preclinical

36 3

Voltaren

Novartis

Preclinical

1 4

Lexiscan

Astellas

Preclinical

1 5

Adenocard

Astellas

Preclinical

1 6

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 7

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 8

Spravato

WWim Janssens

Preclinical

2 9

Acupan

YYonsei University

Preclinical

1 10

Avastin

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalNot yet recruiting

Panic Disorder

NCT05737511

N/ARecruiting

Study completion

NCT05480150

Q1 2027

Post-ApprovalRecruiting

Study completion

NCT05004987

Clinical

Trials by Indication[1]

MACE2 trials

Bioequivalence Study of Torrent Pharmaceutical Ltd.'s of Escitalopram Oxalate Tablets Under Fed Condition

Completed·TTorrent Pharmaceuticals Limited·Phase 1·NCT01996475

Bioequivalence Study of Torrent Pharmaceutical Ltd.'s of Escitalopram Oxalate Tablets Under Fasting Condition

Completed·TTorrent Pharmaceuticals Limited·Phase 1·NCT01996462

Panic Disorder1 trial

Efficacy of Hydroxyzine for Patients With Panic Disorder

Not yet recruiting·SSultan Qaboos University·Phase 4·NCT05737511·80 enrolled

Transcranial Magnetic Stimulation1 trial

Efficacy and Safety of Bifidobacterium Combined With High-frequency Transcranial Magnetic Stimulation in the Treatment of Adolescent Depression

Completed·ZZhen-Hong Hu·N/A·NCT06325605·100 enrolled

Breast Cancer1 trial

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

Completed·MMayo Clinic··NCT00667121·88 enrolled

Treatment1 trial

Brain Imaging and Treatment Studies of the Night Eating Syndrome

Completed·UUniversity of Pennsylvania·Phase 3·NCT01401595·87 enrolled

6 more indications

Effectiveness1 trial

Effectiveness and Safety of Electro-acupuncture for Mild-to-moderate Perimenopausal Depression

Unknown status·GGuangdong Provincial Hospital of Traditional Chinese Medicine·N/A·NCT02423694·252 enrolled

Spinal Cord Injury1 trial

Molecular Markers of Neuroplasticity During Exercise in People With Incomplete Spinal Cord Injury

Completed·TT. George Hornby·N/A·NCT01538693·30 enrolled

Intestinal Cancer1 trial

Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer

Terminated·MMassachusetts General Hospital·Phase 3·NCT00387348·24 enrolled

Depression1 trial

Escitalopram, Placebo and tDCS in Depression: a Non-inferiority Trial

Completed·UUniversity of Sao Paulo·Phase 3·NCT01894815·245 enrolled

Insomnia1 trial

A Clinical Study to Evaluate the Drug Interaction Between YZJ-1139 Tablets and Escitalopram Oxalate Tablets

Completed·SShanghai Haiyan Pharmaceutical Technology Co., Ltd.·Phase 1·NCT06680531·24 enrolled

Unspecified4 trials

Fasting Study of Escitalopram Oxalate Tablets 20 mg and Lexapro® Tablets 20 mg

Completed· Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc·Phase 1·NCT00648570·37 enrolled

Food Study of Escitalopram Oxalate Tablets 20 mg to Lexapro® Tablets 20 mg

Completed· Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc·Phase 1·NCT00648661·35 enrolled

Chinese Longitudinal and Systematic Study of Bioplar Disorder

Recruiting·FFirst Affiliated Hospital of Zhejiang University·N/A·NCT05480150·10,000 enrolled

Show 1 more trial

Aβ Dynamics in LLMD

Recruiting·NNYU Langone Health·Phase 4·NCT05004987·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Escitalopram Oxalate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Escitalopram Oxalate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Escitalopram Oxalate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Torrent Pharmaceuticals Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TTorrent Pharmaceuticals Limited

Escitalopram Oxalate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

MACE2 trials

Panic Disorder1 trial

Transcranial Magnetic Stimulation1 trial

Breast Cancer1 trial

Treatment1 trial

Effectiveness1 trial

Spinal Cord Injury1 trial

Intestinal Cancer1 trial

Depression1 trial

Insomnia1 trial

Unspecified4 trials

References

Drug Info

Quick Facts

Related News